IQVIA Holdings Inc (IQV) Stock Analysis
Verdict: BUY
Robust FCF yield and AI-driven clinical efficiency provide a margin of safety against high leverage and biotech funding cyclicality.
Investment score: 68/100
Analysis as of
Is IQVIA Holdings Inc stock worth reviewing? The TradeMates thesis
IQVIA is transitioning from a traditional CRO to a data-tech hybrid, evidenced by recent market outperformance and strong cash flow generation.
7-factor investment score
- Valuation: 60/100 (weight 20%)
- Financial Health: 65/100 (weight 15%)
- Technical Momentum: 75/100 (weight 15%)
- Earnings Quality: 80/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 70/100 (weight 10%)
- Risk-Adjusted Return: 72/100 (weight 15%)
IQVIA Holdings Inc opportunities and risks
What speaks for IQV
- Superior FCF Generation
What speaks against IQV
- High Debt Service and Liquidity Constraints
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| IQV | 29.9x | 2.4x | 15.6x | 26.2% | 8.1% | 7.2% |
| TMO | 31.0x | 4.6x | 23.1x | 40.4% | 15.1% | 3.4% |
| DHR | 35.2x | 5.6x | 25.2x | 58.5% | 15.9% | 3.9% |
| A | 28.2x | 5.5x | 21.0x | 53.0% | 19.6% | 3.2% |
| WAT | 48.7x | 6.6x | 32.6x | 55.0% | 11.9% | 1.1% |
| ILMN | 34.8x | 6.6x | 21.4x | 67.1% | 19.4% | 3.4% |
| Peer median | 34.8x | 5.6x | 23.1x | 55.0% | 15.9% | 3.4% |
Frequently asked questions about IQVIA Holdings Inc (IQV)
Is IQV stock a good investment?
The TradeMates model rates IQVIA Holdings Inc as BUY with an investment score of 68/100. IQVIA is transitioning from a traditional CRO to a data-tech hybrid, evidenced by recent market outperformance and strong cash flow generation. This is algorithmic model output, not personal investment advice.
Is IQV stock a buy?
The TradeMates model verdict for IQV is BUY with an investment score of 68/100. Treat this as a model signal to review, not a personal buy recommendation.